Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-006?
PR-006 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Frontotemporal Dementia...
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-006?
PR-006 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Frontotemporal Dementia...